Zura Bio

Zura Bio FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Zura Bio (ZURA) as of Nov 3, 2026 is 94.58 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 53.72 % — a change of 76.06% (higher).

FCF Conversion

94.58 %

YoY

76.06%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Zura Bio is 2025 94.58 % . FCF Conversion Rate (FCF/EBITDA) of Zura Bio was 2024 53.72 % . It decreases by 76.06% higher compared to the previous year.

The Zura Bio FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2021
-13.05 USD
Jan 1, 2022
51.29 USD
Jan 1, 2023
38.19 USD
Jan 1, 2024
53.72 USD
Jan 1, 2025
94.58 USD
The Zura Bio FCF Conversion history
YEARFCF ConversionYoY
94.58 %+76.06%
53.72 %+40.65%
38.19 %-25.54%
51.29 %-493.14%
-13.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Zura Bio Stock analysis

What does Zura Bio do? Zura Bio Ltd. develops novel medicines for immune disorders, focusing on clinical-stage therapeutics such as ZB-168 and torudokimab. ZB-168, an anti-IL7Rα inhibitor, targets diseases linked to IL7 and TSLP pathways, building on Phase Ib data in type 1 diabetes. Torudokimab, a monoclonal antibody neutralizing IL33, is in phase II development. The company monetizes through advancing these assets into later-stage clinical programs, leveraging their therapeutic potential for immune-related conditions. Zura Bio Ltd. generates revenue by progressing its pipeline candidates toward regulatory approval and commercialization. The firm's portfolio includes ZB-168 for immune disorders with a demonstrated safety profile in type 1 diabetes, and torudokimab targeting IL33-related conditions. These assets are developed for specific therapeutic indications, with ZB-168 expanding into new immune disorder applications based on existing clinical data. The company's primary revenue stream comes from the advancement of its clinical-stage assets, including ZB-168 and torudokimab, into phase II development. ZB-168 is positioned for diseases involving IL7 and TSLP pathways, while torudokimab addresses IL33-related conditions. Both products are developed for immune disorder treatments, with ZB-168 leveraging Phase Ib data in type 1 diabetes to support further development. Zura Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zura Bio stock

FCF Conversion Rate (FCF/EBITDA) of Zura Bio is 94.58 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Zura Bio changed from 53.72 % to 94.58 %, representing a 76.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Zura Bio since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Zura Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Zura Bio

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Zura Bio